No Products in the Cart


Mounjaro once weekly injection with the most significant weight loss

What is Mounjaro? 

Article Written by: Kimberly Lopez, Charlotte Van Noppen


Mounjaro is an injectable prescription medicine that adults with type 2 diabetes utilize to treat it

Over 30 million Americans aged 18 and over have type 2 diabetes, with greatly increasing numbers of children under 18.

It is a type of medicine composed of GIP (glucose- dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. GIP works by reducing food intake and increasing energy expenditure leading to weight loss. Combining this with a GLP-1 receptor agonist leads to a greater impact on blood glucose and body weight.

Although Mounjaro is not a weight loss drug, it does also help individuals lose extra weight, aiding in the management of their diabetes long-term.It has recently been approved by the FDA for use in the US and has resulted in significant weight loss (over 15% body weight loss) and appetite suppression compared to existing GLP receptor agonists.

The medication has been accepted for adults with type 2 diabetes but not for children or teens or people with type 1 diabetes.

Mounjaro has been found to be more successful at treating type 2 diabetes when compared to other diabetes therapies availabl

“Mounjaro is the first dual GIP and GLP-1 receptor agonist to be approved by the FDA.

Mounjaro has various functions including increasing insulin production when the blood sugar is increasing which ultimately reduces the risk of high blood sugar. It also decreases the liver’s production of sugar and reduces the speed at which the stomach empties food into the intestine, resulting in a feeling of prolonged fullness. 

The medication is curated to help imitate both agonists (GIP and GLP-1) in binding to their receptors. This mechanism is what helps maintain glucose levels aiding in weight loss. 

Side Effects 

There are possible side effects that can occur when using Mounjaro including nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, etc. Some of the more serious side effects are thyroid tumors and even cancer. Therefore, it is important to avoid this medication if there is family history of any type of thyroid cancer or endocrine system conditions. 

To reduce the severity of the side effects, it is recommended to begin at 5 mg and gradually increase the dose with the assistance of your primary care doctor. If a dose is missed, it is recommended that Mounjaro should be taken as soon as possible within 4 days after the missed dose. If more than 4 days have passed, you should skip the missed dose and instead continue with the regularly scheduled day. 

Before using Mounjaro, it is critical to notify your healthcare provider of any existing medical conditions and any other current medications that you are using. 

Dr. Belardo can help you manage and guide you with this medication.

Mounjaro is typically injected under the skin on your stomach, thigh, or upper arm about once a week during any time of the day. 

An important note to take when utilizing Mounjaro is that it should not be mixed with insulin in the same injection. You are allowed to inject both substances in the same area, however, not right next to each other. 

Studies have shown that Mounjaro goes beyond weight loss as it has improved A1c levels, reduced risk of hypoglycemia, and total levels of triglycerides and cholesterol.

Based on the information provided, 3 out of 4 individuals receiving injections of Manjaro lowered their A1C to under 7%. A1C is a standard blood test that measures your blood glucose levels. The lower your A1C level, the lower your risk of diabetes. The ideal range for A1C is below 5.7%.

In terms of weight loss, Mounjaro has displayed the most significant weight loss when compared to other diabetes medications. After a year, the average weight loss was around 25 pounds. Those taking the highest dose of 15 mg lost about 27 pounds and individuals on the lowest dose lose about 17 pounds. 

  • Patients with an average body mass index of 32 to 34, qualifying them as obese, lost an average of 12-25 pounds more than participants receiving a placebo injection or other injections that are available to treat diabetes, such as Ozempic.